Aurobindo Pharma trades near 52-wk low as Hyd units come under US FDA lens

The management believes that these observations are related to procedural improvements and none of the observations are related to data integrity.

Shares of Aurobindo Pharma dipped 5 per cent to Rs 448, in otherwise firm market, on the BSE on Wednesday after the US health regulator (US FDA) issued ‘Form 483’ with four observations for its Hyderabad facilities. The stock of the drug firm was trading close to its 52-week low of Rs 435 touched on October 11, 2019 in the intra-day trade.

“The United States Food and Drug Administration (US FDA) inspected Unit V, API manufacturing facility at Pashamylaram, Hyderabad and Unit VIII, API manufacturing facility at Gaddapotharam, Hyderabad of the Company from 21st to 28th October 2019 and from